Description
Bronchogen is the synthetic tetrapeptide Ala-Glu-Asp-Leu (AEDL), assigned by its St. Petersburg developers to the bronchial epithelium and studied mainly in an embryonic bronchial cell line, a rat model of nitrogen dioxide exposure and cell-free DNA-binding experiments. Pure Peptides Canada supplies it as a lyophilized research reagent in 20 mg vials, with an independent Janoshik HPLC and mass-spectrometry report, CAD pricing and tracked shipping from inside Canada.
Bronchogen at a glance
- What it is: L-alanyl-L-glutamyl-L-aspartyl-L-leucine (AEDL), a synthetic tetrapeptide from Vladimir Khavinson’s bioregulator programme.
- What researchers study: differentiation and mucin-gene expression in cultured bronchial epithelial cells, airway remodelling after nitrogen dioxide exposure in rats, and how an acidic tetrapeptide binds DNA and histones.
- Evidence level: a small number of cell-culture, rat and test-tube DNA studies, nearly all from the developer’s group or its collaborators; we found no peer-reviewed controlled trial in people.
- Supplied as: sealed lyophilized powder, 20 mg, single vial or box of 10.
- Delivery: ships from inside Canada by tracked Xpresspost in 3–7 days ($25 CAD), or free in 4–12 days on orders over $299.
Bronchogen
Ala-Glu-Asp-Leu · AEDL tetrapeptide · bronchial bioregulator
- A
- E
- D
- L
Black: the Ala-Glu-Asp core shared with Cardiogen, Cortagen, Cartalax and Epithalon. Blue: the leucine that distinguishes Bronchogen.
- Length
- 4 amino acids
- Molecular formula
- C18H30N4O9
- Molecular weight
- ≈ 446.5 g/mol
- Family
- Khavinson short-peptide bioregulators
- Form
- Lyophilized powder, sealed vial
- Sizes
- 20 mg (single or box of 10)
- SKU
- PP-BRONCHOGEN
Where the evidence stands
- Cell studies
- Animal models
- Controlled human trials
- Approved medicine
Published work comes mainly from the group that developed it. Bronchogen is not an approved medicine.
What is Bronchogen?
Bronchogen is a four-residue peptide synthesized at the St. Petersburg Institute of Bioregulation and Gerontology and assigned by its developers to the airway lining. Its first three residues, Ala-Glu-Asp, are shared with Epithalon (AEDG), Cardiogen (AEDR) and Cortagen (AEDP), and are sold on their own as Cartalax; the C-terminal leucine is what sets Bronchogen apart. Its closest relative in the catalogue is Ovagen (Glu-Asp-Leu), which is Bronchogen without the N-terminal alanine and is usually sold as liver- and gut-associated, a link we could not trace to a primary paper.
With two acidic residues and no basic ones, Bronchogen carries a net negative charge at neutral pH, so its reported binding to DNA was unexpected even to its authors, who placed the contact at guanine N7 in the major groove (Khavinson et al., Lung, 2014). Anyone comparing papers should note a sequence discrepancy: the 2011 calorimetry study and the 2014 Lung study print the peptide as Ala-Asp-Glu-Leu (ADEL), while a 2011 binding study, a 2017 DNA study and the group’s 2021 review give Ala-Glu-Asp-Leu (AEDL), the sequence this reagent is supplied as. The two contain the same four amino acids in a different order, and the papers we reviewed do not explain the difference.
What published studies report
The studies below are the ones whose abstracts or full texts we could read. Each is a single report, nearly all from Khavinson’s group or its collaborators, and we found no independent replication of the cell-culture results.
- Bronchial epithelial cells (2014): in the FLECH line of human embryonic bronchial epithelial cells, grown to early, middle and late passages, the peptide raised the proliferation marker Ki67 and the survival protein Mcl-1, lowered p53, and increased expression of airway differentiation and secretory genes including NKX2-1, SCGB1A1, FOXA2, MUC4, MUC5AC and SFTPA1 (Khavinson et al., Lung, 2014). One cell line at one concentration, with no animal or human arm.
- Rat airways after nitrogen dioxide (2015): in a rat model of obstructive lung disease produced by 60 days of intermittent nitrogen dioxide exposure, animals given Bronchogen for one month showed less goblet-cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema, recovery of ciliated cells and more secretory IgA, according to the authors (Kuzubova et al., Bulletin of Experimental Biology and Medicine, 2015). A short report in a single animal model; it does not show any effect in people.
- DNA thermostability (2011): by differential scanning microcalorimetry, the peptide raised the melting temperature of calf-thymus and mouse-liver DNA by 3.1 °C at low peptide-to-base-pair ratios, with no preference for A–T or G–C pairs (Monaselidze et al., Bulletin of Experimental Biology and Medicine, 2011). Cell-free chemistry.
- Sequence-selective binding (2011, 2017): in fluorescence-quenching assays it bound short DNA strands containing CNG motifs, especially CTG, and favoured methylated cytosine (Fedoreyeva et al., Biochemistry (Moscow), 2011); spectroscopy and viscometry later confirmed a complex with high-molecular-weight DNA in solution (Morozova et al., Journal of Structural Chemistry, 2017). Both used purified DNA, not cells.
- Plant chromatin (2020): in tobacco plants grown with the peptide, the share of condensed chromatin domains fell from 45% in control cells to 25%, and the peptide bound linker histone H1 and histone–DNA complexes (Fedoreyeva et al., AIMS Biophysics, 2020). A plant model, useful for mechanism questions but not for airway biology.
Reported in studies
- Gene and protein changes in one embryonic bronchial cell line
- Less airway remodelling in one rat nitrogen dioxide model
- Binding to DNA and histones in cell-free and plant systems
Not established
- Whether the cell results hold in adult airway cells or in other laboratories
- How DNA binding would lead to the reported gene changes
- Whether every study used the same sequence (AEDL or ADEL)
- Any effect in humans; we found no peer-reviewed controlled trial in people
Regulatory status: Bronchogen is not an authorized drug in Canada. We sell it strictly as a laboratory reagent for in-vitro research.
Why researchers order Bronchogen from Pure Peptides Canada
Add a 20 mg vial or a box of 10 above. Orders over $299 ship free across Canada.
See lab resultsBronchogen FAQ
Where can I buy Bronchogen in Canada?
Pure Peptides Canada stocks Bronchogen as a lyophilized research reagent in 20 mg vials and ships it from inside Canada by tracked Xpresspost in 3–7 days ($25 CAD), or free in 4–12 days on orders over $299.
What is the difference between Bronchogen and Chonluten?
Both are airway-associated bioregulators from the same programme. Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu; Chonluten is the tripeptide Glu-Asp-Gly.
Is Bronchogen Ala-Glu-Asp-Leu or Ala-Asp-Glu-Leu?
This reagent is Ala-Glu-Asp-Leu (AEDL), the order used in most of the developers’ papers we checked. Two of their papers, a 2011 calorimetry study and the 2014 Lung cell study, print it as Ala-Asp-Glu-Leu (ADEL), so check which sequence a paper describes before comparing results.
What has Bronchogen been studied in?
An embryonic human bronchial epithelial cell line, a rat model of nitrogen dioxide exposure, cell-free DNA and histone binding assays, and tobacco plants. We found no peer-reviewed controlled trial in people.
Can Bronchogen be used in people or animals?
No. This product is for in-vitro laboratory research only and is not a drug, supplement or food. We do not provide dosing or administration information.
References
- Khavinson VKh, Tendler SM, Vanyushin BF, et al. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781–791. DOI
- Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, et al. Effect of the peptide Bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med. 2011;150(3):375–377. DOI
- Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210–1219. DOI
- Morozova EA, Lin’kova NS, Khavinson VKh, et al. In vitro interaction of the AEDL peptide with DNA. J Struct Chem. 2017;58(2):420–424. DOI
- Fedoreyeva LI, Vanyushin BF, Baranova EN. Peptide AEDL alters chromatin conformation via histone binding. AIMS Biophys. 2020;7(1):1–16. DOI
- Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, et al. Modulating effect of peptide therapy on the morphofunctional state of bronchial epithelium in rats with obstructive lung pathology. Bull Exp Biol Med. 2015;159(5):685–688. DOI
- Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. DOI
For laboratory research use only. Not a drug, supplement, food or cosmetic, not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Ella Jones –
Reparing my lungs one dose at a time. I know this is “research only” and “research chemicals” and the stigma with those claims. They just dont want you to know that we have the power to cure ourselves with these peptides. I was skeptical but I was left with no more options so now im on this path and its working. Thanks a million!